{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:46:16Z","timestamp":1789775176303,"version":"4.0.1"},"reference-count":23,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2022,12,25]]},"DOI":"10.5582\/ddt.2022.01085","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T22:23:16Z","timestamp":1666909396000},"page":"297-299","source":"Crossref","is-referenced-by-count":24,"title":["Valemetostat: First approval as a dual inhibitor of EZH1\/2 to treat adult T-cell leukemia\/lymphoma"],"prefix":"10.5582","volume":"16","author":[{"given":"Fangzhou","family":"Dou","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxue","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Qingdao Municipal Hospital, Qingdao, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Qingdao Municipal Hospital, Qingdao, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruquan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Katsuya H, Ishitsuka K, Utsunomiya A, <i>et al<\/i>. Treatment and survival among 1594 patients with ATL. Blood. 2015; 126:2570-2577.","DOI":"10.1182\/blood-2015-03-632489"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hermine O. ATL treatment: Is it time to change? Blood. 2015; 126:2533-2534.","DOI":"10.1182\/blood-2015-10-670489"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Imaizumi Y, Iwanaga M, Nosaka K, <i>et al<\/i>. Prognosis of patients with adult T-cell leukemia\/lymphoma in Japan: A nationwide hospital-based study. Cancer Sci. 2020; 111:4567-4580.","DOI":"10.1111\/cas.14658"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: A review of epidemiological evidence. Front Microbiol. 2012; 3:322.","DOI":"10.3389\/fmicb.2012.00322"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sakamoto H, Itonaga H, Sawayama Y, <i>et al<\/i>. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki Transplant Group experience. Hematol Oncol. 2020; 38:162-170.","DOI":"10.1002\/hon.2712"},{"key":"6","unstructured":"6. Daiichi Sankyo. EZHARMIA Approved in Japan as First Dual EZH1 and EZH2 Inhibitor Therapy for Patients with Adult T-Cell Leukemia\/Lymphoma. <i>https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202209\/20220926_E.pdf<\/i> (accessed October 15, 2022)."},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Izutsu K, Makita S, Nosaka K, <i>et al<\/i>. An open-label, single-arm, phase 2 trial of valemetostat in relapsed or refractory adult T-cell leukemia\/lymphoma. Blood. 2022. doi: 10.1182\/blood.2022016862.","DOI":"10.1182\/blood.2022016862"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Duan R, Du W, Guo W. EZH2: A novel target for cancer treatment. J Hematol Oncol. 2020; 13:104.","DOI":"10.1186\/s13045-020-00937-8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Fujikawa D, Nakagawa S, Hori M, <i>et al<\/i>. Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood. 2016; 127:1790-1802.","DOI":"10.1182\/blood-2015-08-662593"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gan L, Xu M, Hua R, Tan C, Zhang J, Gong Y, Wu Z, Weng W, Sheng W, Guo W. The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter. J Hematol Oncol. 2018; 11:9.","DOI":"10.1186\/s13045-017-0547-3"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Krill L, Deng W, Eskander R, Mutch D, Zweizig S, Hoang B, Ioffe O, Randall L, Lankes H, Miller DS, Birrer M. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology\/Gynecologic Oncology Group Study. Gynecol Oncol. 2020; 156:423-429.","DOI":"10.1016\/j.ygyno.2019.12.003"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sashida G, Iwama A. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies. Int J Hematol. 2017; 105:23-30.","DOI":"10.1007\/s12185-016-2124-x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Bodor C, O&apos;Riain C, Wrench D, <i>et al<\/i>. EZH2 Y641 mutations in follicular lymphoma. Leukemia. 2011; 25:726-729.","DOI":"10.1038\/leu.2010.311"},{"key":"14","unstructured":"14. US Food and Drug Administration. FDA approves tazemetostat for advanced epithelioid sarcoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tazemetostat-advanced-epithelioid-sarcoma (accessed October 22, 2022)."},{"key":"15","unstructured":"15. US Food and Drug Administration. FDA granted accelerated approval to tazemetostat for follicular lymphoma. <i>https:\/\/www.fda.gov\/drugs\/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma <\/i>(accessed October 22, 2022)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Yamagishi M, Hori M, Fujikawa D, <i>et al<\/i>. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 2019; 29:2321-2337 e2327.","DOI":"10.1016\/j.celrep.2019.10.083"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Honma D, Kanno O, Watanabe J, <i>et al<\/i>. Novel orally bioavailable EZH1\/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor. Cancer Sci. 2017; 108:2069-2078.","DOI":"10.1111\/cas.13326"},{"key":"18","unstructured":"18. Clinical trials registration. <i>https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=valemetostat&amp;term=&amp;cntry=&amp;state=&amp;city=&amp;dist=<\/i> (accessed October 16, 2022)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ishitsuka K, Izutsu K, Maruyama D, <i>et al<\/i>. First-in-human study of the EZH1 and EZH2 dual inhibitor valemetostat tosylate (DS-3201b) in patients with relapsed or refractory non-hodgkin lymphomas. Hematol Oncol. Supplement Abstract. <i>https:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/hon.14_2879<\/i> (accessed October 23, 2022).","DOI":"10.1002\/hon.14_2879"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Arakawa A, Ozawa H, Hirakawa A, Sadachi R, Hoshina Y, Tomatsuri S, Saito Y, Ando RM, Terashima K, Nakamura K, Ogawa C. Trial in progress: A phase I trial of dual EZH 1\/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric, adolescent, and young adult patients with malignant solid tumors. J Clin Oncol. 2022; 40(suppl).","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS10059"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Chen XX, Shen QQ, Zhao Z, Fang YF, Yang JY, Gao YL, Liu L, Zhang Y, Chen Y, Li L. Abstract 5436: HH2853 is a selective small molecular dual inhibitor of EZH1\/2 with potent anti-tumor activities. Cancer Res. 2022; 82:5436-5436.","DOI":"10.1158\/1538-7445.AM2022-5436"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Jung SH, Hong D, Hwang J, Park S, Byun J, Lee M, Koo K, Lee G, Kim YY, Bak Y, Ahn YG, Kim Y, Suh KH. Abstract 1142: A novel and potent EZH1\/2 dual inhibitor, HM97662, demonstrates antitumor activity in malignant tumors. Cancer Res. 2021; 81:1142-1142.","DOI":"10.1158\/1538-7445.AM2021-1142"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Jung SH, Hong D, Kim S, <i>et al<\/i>. A novel and potent EZH1\/2 dual inhibitor HM97594 for the treatment of hematological malignancies. Blood. 2019; 134(supplement_1):4648.","DOI":"10.1182\/blood-2019-122982"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/16\/6\/16_2022.01085\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T04:15:52Z","timestamp":1672460152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/16\/6\/16_2022.01085\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,25]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2022.01085","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,25]]},"article-number":"2022.01085"}}